GLP-1 Gastroparesis Reviewed as Aspiration Questions Persist

What the PLOS One systematic review of GLP-1 gastroparesis examined

The review, published in PLOS One and authored by Olubodun, Osundina, Soyoye and colleagues, is titled "Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes." Those four categories are the structure of the paper. Rather than testing whether the drugs cause gastroparesis, the authors set out to describe what the published cases look like when clinicians encounter them.

That is a specific and useful editorial choice. Clinical features means the symptom picture — the pattern of nausea, vomiting, early fullness, bloating and abdominal pain that brings someone in. Diagnosis means how the delay in stomach emptying was confirmed, which in practice involves tests such as gastric emptying studies. Management covers what clinicians did about it, and outcomes covers whether it resolved.

The PubMed record currently carries abstract-level detail, so the number of cases pooled and the specific agents involved are best read in the full paper. What the review's existence signals is that enough individual reports have accumulated for someone to consider them worth systematically collating.

How is GLP-1 gastroparesis different from ordinary nausea on these drugs?

Slowing gastric emptying is not a side effect of GLP-1 receptor agonists in the sense of being an unintended accident. It is part of how the class works. Activating GLP-1 receptors delays the passage of food from the stomach into the small intestine, which contributes to the sensation of fullness and to reduced food intake. The nausea, early satiety and occasional vomiting that many users report early in treatment are the everyday expression of that mechanism.

Gastroparesis is the same phenomenon at a severity that stops being tolerable. The term describes markedly delayed gastric emptying without a mechanical obstruction, producing persistent vomiting, inability to keep food down, weight loss beyond what was intended, and in some cases retained stomach contents on imaging or endoscopy hours after eating. The distinction between the common effect and the clinical syndrome is one of degree, duration and functional impact.

Because the boundary is a matter of degree, the labels people use casually online are unreliable. A week of nausea after a change in therapy and a persistent vomiting syndrome requiring a gastric emptying study are not the same event, and conflating them makes personal symptom records less useful to a clinician.

Structured side-effect logging that captures onset date, duration and whether vomiting occurred is what separates a usable clinical timeline from a vague recollection.

The anaesthesia question: what happens to gastric contents after semaglutide is stopped?

The Anaesthesia letter, authored by Chang and titled "Gastric content and aspiration risk after semaglutide cessation," addresses a narrower and more procedural question. Aspiration is the entry of stomach contents into the airway, a recognised hazard of general anaesthesia and sedation. Standard practice manages that risk through fasting before a procedure, on the assumption that a fasted stomach is an empty one.

Drugs that delay gastric emptying complicate that assumption, which is why anaesthesiology bodies have issued guidance in recent years on incretin drugs before elective procedures. The question Chang's letter engages is what happens after the drug is stopped: how quickly gastric contents return to what a fasting protocol assumes, and therefore whether stopping the medicine for a period before a procedure reliably resolves the concern.

As a letter, this is a contribution to an ongoing argument rather than a definitive study. It is being published because the underlying evidence — imaging studies of residual gastric contents in people using these drugs — remains limited and inconsistent, and because clinicians need to make practical decisions in the meantime.

Readers who need to state their most recent administration accurately on a pre-procedure form often reconstruct it from the same records they keep alongside a semaglutide dosage calculator.

Why procedural teams care about residual stomach contents

From an anaesthesia standpoint, the relevant question is not whether a patient feels full but whether there is measurable material in the stomach when the airway reflexes are suppressed. Point-of-care gastric ultrasound has become one way of answering that at the bedside, and reports of unexpected residual contents in fasted patients on GLP-1 receptor agonists are what drove the guidance conversation in the first place.

The practical consequences of that assessment vary: a procedure may be delayed, the fasting window may be extended, or the airway may be managed differently. None of those decisions can be made from a published letter or from a patient's own reading. They depend on the individual, the procedure, the drug and the timing, and they are made by the anaesthesia team.

What patients can do is make sure the team knows. An incretin drug obtained through a compounding pharmacy or a telehealth service is easy to omit from a pre-operative medication list, particularly if the person does not think of it as a prescription medicine in the same category as their other ones.

Because timing relative to the last administration is the variable procedural teams ask about, adherence tracking that records actual dates rather than intended ones is more useful than a schedule on paper.

What a systematic review of case reports can and cannot show

Systematic reviews sit high in the evidence hierarchy when they pool randomised trials. When they pool case reports, as reviews of a rare complication generally must, they inherit the limitations of the underlying material. Case reports are published selectively — striking presentations are more likely to be written up than mild ones — so the pooled picture describes the severe end of a distribution rather than its centre.

That means the PLOS One review can reasonably describe how GLP-1-associated gastroparesis tends to present, what tests confirmed it and what happened next, but it cannot say how many users develop it. Incidence requires a denominator: cohort studies, claims databases or trial safety datasets in which everyone exposed is counted, not just those whose cases were interesting enough to publish.

Read with that limitation in mind, the review is a pattern-recognition tool. It helps a clinician who is looking at a persistent vomiting syndrome in a patient on an incretin drug know what has been reported before.

The PLOS One systematic review by Olubodun, Osundina, Soyoye and colleagues examines clinical features, diagnosis, management and outcomes in published cases of gastroparesis induced by GLP-1 receptor agonists. the PLOS One systematic review.

What remains unresolved

Three questions stay open. First, incidence: how often severe delayed emptying occurs across the class and whether it differs between semaglutide, tirzepatide and the others. Second, reversibility: whether symptoms consistently resolve after discontinuation and over what period, which is exactly the territory Chang's letter probes from the anaesthesia side. Third, prediction: whether pre-existing conditions such as long-standing diabetes with autonomic involvement identify people at higher risk.

Answering the aspiration question specifically will require prospective imaging studies with fasting protocols and defined intervals after the last dose. Until that exists, guidance will keep being revised, and the pre-procedure conversation will keep being individualised.

A letter in Anaesthesia by Chang addresses gastric content and aspiration risk after semaglutide cessation, the question underlying pre-procedure guidance for these drugs. a letter in Anaesthesia.